Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume
NCT: NCT07528781 · RECRUITING
Brief Summary
The goal of this observational study is demonstrate that a novel artificial intelligence based software for the quantification of the mitral regurgitation on 3-dimensional transesophageal echocardiography (3D CFQ) is more reproducible and accurate than the conventional assessment of mitral regurgitation performed with 2-dimensional echocardiography. The main question aims to answer is to demonstrate the agreement between 3D-CFQ measurement of the mitral regurgitant volume and the cardiac magnetic resonance measurement of the regurgitant volume is better than the agreement between 2-dimensional echocardiography and cardiac magnetic resonance. If this is demonstrated, we would like to test the accuracy of this tool to be applied in acute settings such as transcatheter interventions to decide the therapy to follow. Participants will undergo clinically indicated transesophageal echocardiography to characterize the mechanism and severity of mitral regurgitation and to cardiac magnetic resonance to be used as reference stadard to define the mitral regurgitation severity.
Frequently Asked Questions
What is Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume?
Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume is a clinical trial registered under NCT07528781. Current status: RECRUITING.
What is the status of NCT07528781?
The current status of NCT07528781 (Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume) is: RECRUITING.
When did Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume start?
Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume started on 2026-03-17.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.